Barclays PLC lowered shares of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) from an overweight rating to an equal weight rating in a research note issued to investors on Thursday morning. The firm currently has $50.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $85.00.
Several other brokerages have also recently issued reports on ALNY. Needham & Company LLC reaffirmed a buy rating and issued a $152.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, August 5th. Cowen and Company reaffirmed a buy rating and issued a $150.00 target price on shares of Alnylam Pharmaceuticals in a report on Sunday, August 7th. Janney Montgomery Scott assumed coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 28th. They issued a neutral rating and a $74.00 target price for the company. Jefferies Group set a $86.00 target price on shares of Alnylam Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, September 28th. Finally, Goldman Sachs Group Inc. reissued a neutral rating and set a $65.00 price objective (up from $63.00) on shares of Alnylam Pharmaceuticals in a report on Wednesday, August 10th. Eight equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average price target of $80.88.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 35.52 on Thursday. The stock’s market capitalization is $3.04 billion. Alnylam Pharmaceuticals has a 1-year low of $33.16 and a 1-year high of $110.75. The firm has a 50-day moving average of $69.62 and a 200 day moving average of $65.95.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.24) by $0.19. The business earned $8.70 million during the quarter, compared to analysts’ expectations of $8.09 million. Alnylam Pharmaceuticals had a negative net margin of 1,204.91% and a negative return on equity of 29.60%. The business’s revenue for the quarter was up .2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.85) earnings per share. Analysts predict that Alnylam Pharmaceuticals will post ($4.68) EPS for the current year.
In related news, CEO John Maraganore sold 30,151 shares of the company’s stock in a transaction on Wednesday, July 20th. The shares were sold at an average price of $64.69, for a total transaction of $1,950,468.19. Following the completion of the transaction, the chief executive officer now owns 148,465 shares in the company, valued at $9,604,200.85. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 4.00% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. Altrinsic Global Advisors LLC bought a new position in shares of Alnylam Pharmaceuticals during the first quarter worth $4,250,000. AXA raised its position in shares of Alnylam Pharmaceuticals by 50.5% in the first quarter. AXA now owns 98,689 shares of the biopharmaceutical company’s stock worth $6,195,000 after buying an additional 33,116 shares in the last quarter. State Street Corp raised its position in shares of Alnylam Pharmaceuticals by 15.7% in the first quarter. State Street Corp now owns 1,936,520 shares of the biopharmaceutical company’s stock worth $121,553,000 after buying an additional 262,783 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Alnylam Pharmaceuticals by 348.1% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,321 shares of the biopharmaceutical company’s stock worth $836,000 after buying an additional 10,348 shares in the last quarter. Finally, Credit Agricole S A raised its position in shares of Alnylam Pharmaceuticals by 11.6% in the first quarter. Credit Agricole S A now owns 12,182 shares of the biopharmaceutical company’s stock worth $765,000 after buying an additional 1,270 shares in the last quarter. Hedge funds and other institutional investors own 85.96% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.